Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study

• Published in: Antimicrobial Agents and Chemotherapy 1992-05, Vol.36 (5), p.1062-1067
• Main Authors: RAMPHAL, R, BOLGER, M, OBLON, D. J, SHERERTZ, R. J, MALONE, J. D, RAND, K. H, GILLIOM, M, SHANDS, J. W, KRAMER, B. S
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Bacteria - isolation & purification; Biological and medical sciences; Ceftazidime; Ceftazidime - administration & dosage; Ceftazidime - therapeutic use; Drug Therapy, Combination - therapeutic use; Female; Fever - drug therapy; Humans; Male; Medical sciences; Middle Aged; Neutropenia; Neutropenia - drug therapy; Neutropenia - microbiology; Pharmacology. Drug treatments; Prospective Studies; Random Allocation; Research Article; Superinfection - prevention & control; Vancomycin; Vancomycin - administration & dosage; Vancomycin - therapeutic use
• ISSN: 0066-4804; 1098-6596
• DOI: 10.1128/AAC.36.5.1062

Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy AAC RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • [e-mail] Print ISSN: 0066-4804 Online ISSN: 1098-6596 Copyright © 2014 by the American Society for Microbiology.   For an alternate route to AAC .asm.org, visit: AAC